In January 2008 ImmunoVaccine Technologies Inc agreed to acquire Immunotope Inc. with the small firm operating as a subsidiary of ImmunoVaccine Technologies, Inc. Immunotope, Inc., a clinical stage biotechnology company, develops immunotherapy products for the treatment and prevention of cancer and chronic viral infections. The company focuses on the unmet need to diagnose cancer at its earliest stages and to provide effective treatments that destroy tumors and prevent recurrence and metastasis. Its products include IMT-1012, an OCPM immunotherapeutic vaccine and a multivalent cancer therapeutic mixture of various novel antigens that targets a pathway present in tumors for the treatment of ovarian, colon, and breast cancer; and an investigational new drug application for ovarian cancer patients. The companys clinical and preclinical programs consist of a cancer immunotherapy program to elicit immunity in the patient to destroy tumor cells; pre clinical and cancer diagnostics programs; and an infectious disease program that focuses on immunotherapeutics for chronic viral diseases, including hepatitis B/C and HIV. In addition, it offers various novel antigens, including ovarian tumor antigens, breast tumor antigens, antibody therapeutic targets, cancer diagnostic targets, and ovarian and prostate theranostic targets for clinical evaluation and out licensing. Further, the company provides immunoproteomics services for antigen discovery and characterization, which include the analysis of MHC processing of proteins in genetic constructs and the analysis of antigen specificity post cell-based immunotherapies. It uses immunoproteomics technologies to identify naturally processed and presented antigens associated with histocompatibility complex class I and class II molecules present on diseased cells
